News

MERLIN TIMI-36 (metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary syndromes) was a multi-national, double-blind, randomized, placebo-controlled, parallel-group clinical trial designed to evaluate the

The renewals complement existing agreements for hematology, flow cytometry and coagulation systems, already on contract with MedAssets. Mary Ellen Kimmeth, MedAssets vice president of laboratory division and capital

The results from the MERLIN TIMI-36 study confirm that Renexa is a safe and effective anti-ischemic drug that also has favorable effects on arrhythmia and hemoglobin A1c, according

The integration uses Boston Scientific’s Latitude patient management system to allow clinicians to access information from a patient’s implanted cardiac device and store within the GE Centricity electronic

The option was granted in connection with Nanosphere’s initial public offering of 7,000,000 shares. The closing of the sale of all 8,050,000 shares by Nanosphere to the underwriters

The Phase Ib study of GI-5005 demonstrated strong trends for a dose-dependent response in patients that normalize their ALT (a marker of liver damage) compared with placebo, ranging

While there was a statistically significant improvement in NYHA class, a secondary endpoint, there was no improvement in quality-of-life, six-minute walk or echocardiographic measures in the patients who

This approval is based on results from a six-week, randomized, double- blind, placebo-controlled study that demonstrated significant improvement with Abilify compared to placebo on the primary efficacy endpoint,

This Phase II study was designed to assess the pharmacokinetics, safety and efficacy of MTR106 in female patients suffering from migraine without aura. The study population consisted of